|
from the nci cancer.gov site
pazopanib hydrochloride
The hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Code name: GW786034
it is made by Glaxo and seems to be being tried mainly in kidney cancer, ovarian Cancer, and neuroendocrine tumors (eg Islet cell tumors of the pancreas) so far
|